knowledge -WSS

knowledge

author：entertainment 2025-09-27 12:57:26 - browse：17761

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： How to make AI work for medicine

hotspot

WSS

Parkland mass shooting to be reenacted for lawsuit

Parkland mass shooting to be reenacted for lawsuit

In science, is the line between industry and academia shifting?

Special counsel alerts court to Trump’s social media post

Winners, losers from Medicare’s list of drugs subject to price talks

CDC advisory panel says seniors 'may' get RSV vaccine

focus

knowledge

focus

Apple is now the first public company to be valued at $3 trillion

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

Duchenne breakthrough therapy leaves behind pioneering families

Psilocybin's anti

Sports medicine is finally prioritizing gender equality

Complete sequence of Y chromosome published for first time

Continuity nursing helped my family in our darkest PICU moments

Winners, losers from Medicare’s list of drugs subject to price talks

Trump demands the U.S. pay no more for drugs than other countries … again

Tuesday set an unofficial record for the hottest day on Earth. Wednesday may break it.

knowledge

Pediatricians' group reaffirms support for gender

Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS

CDC advisory panel says seniors 'may' get RSV vaccine

Eat, drink, but be wary — 4 foods that interact with medications

Slain Parkland victim's father speaks out following reenactment

Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS

hotspot

focus

knowledge

hotspot